410 related articles for article (PubMed ID: 31375583)
1. Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection.
Wu Y; Xue J; Wang C; Li W; Wang L; Chen W; Prabakaran P; Kong D; Jin Y; Hu D; Wang Y; Lei C; Yu D; Tu C; Bardhi A; Sidorov I; Ma L; Goldstein H; Qin C; Lu L; Jiang S; Dimitrov DS; Ying T
J Virol; 2019 Oct; 93(20):. PubMed ID: 31375583
[TBL] [Abstract][Full Text] [Related]
2. Potent
Bardhi A; Wu Y; Chen W; Li W; Zhu Z; Zheng JH; Wong H; Jeng E; Jones J; Ochsenbauer C; Kappes JC; Dimitrov DS; Ying T; Goldstein H
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794022
[TBL] [Abstract][Full Text] [Related]
3. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.
Julg B; Pegu A; Abbink P; Liu J; Brinkman A; Molloy K; Mojta S; Chandrashekar A; Callow K; Wang K; Chen X; Schmidt SD; Huang J; Koup RA; Seaman MS; Keele BF; Mascola JR; Connors M; Barouch DH
J Virol; 2017 Aug; 91(16):. PubMed ID: 28539448
[TBL] [Abstract][Full Text] [Related]
4. Early antibody therapy can induce long-lasting immunity to SHIV.
Nishimura Y; Gautam R; Chun TW; Sadjadpour R; Foulds KE; Shingai M; Klein F; Gazumyan A; Golijanin J; Donaldson M; Donau OK; Plishka RJ; Buckler-White A; Seaman MS; Lifson JD; Koup RA; Fauci AS; Nussenzweig MC; Martin MA
Nature; 2017 Mar; 543(7646):559-563. PubMed ID: 28289286
[TBL] [Abstract][Full Text] [Related]
5. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
6. SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.
Dashti A; Waller C; Mavigner M; Schoof N; Bar KJ; Shaw GM; Vanderford TH; Liang S; Lifson JD; Dunham RM; Ferrari G; Tuyishime M; Lam CK; Nordstrom JL; Margolis DM; Silvestri G; Chahroudi A
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817214
[TBL] [Abstract][Full Text] [Related]
7. Immune Responses and Viral Persistence in Simian/Human Immunodeficiency Virus SHIV.C.CH848-Infected Rhesus Macaques.
Ziani W; Bauer A; Lu H; Wang X; Wu X; Bar KJ; Li H; Liu D; Shaw GM; Veazey RS; Xu H
J Virol; 2021 Apr; 95(9):. PubMed ID: 33568508
[TBL] [Abstract][Full Text] [Related]
8. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
9. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
[TBL] [Abstract][Full Text] [Related]
10. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
[TBL] [Abstract][Full Text] [Related]
11. Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.
Pegu A; Xu L; DeMouth ME; Fabozzi G; March K; Almasri CG; Cully MD; Wang K; Yang ES; Dias J; Fennessey CM; Hataye J; Wei RR; Rao E; Casazza JP; Promsote W; Asokan M; McKee K; Schmidt SD; Chen X; Liu C; Shi W; Geng H; Foulds KE; Kao SF; Noe A; Li H; Shaw GM; Zhou T; Petrovas C; Todd JP; Keele BF; Lifson JD; Doria-Rose NA; Koup RA; Yang ZY; Nabel GJ; Mascola JR
Cell Rep; 2022 Jan; 38(1):110199. PubMed ID: 34986348
[TBL] [Abstract][Full Text] [Related]
12. Protection of Newborn Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy during Breastfeeding.
Rosenberg YJ; Jiang X; Cheever T; Coulter FJ; Pandey S; Sack M; Mao L; Urban L; Lees J; Fischer M; Smedley J; Sidener H; Stanton J; Haigwood NL
J Virol; 2021 Aug; 95(18):e0026821. PubMed ID: 34190597
[TBL] [Abstract][Full Text] [Related]
13. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection.
Mori K; Yasutomi Y; Sawada S; Villinger F; Sugama K; Rosenwith B; Heeney JL; Uberla K; Yamazaki S; Ansari AA; Rübsamen-Waigmann H
J Virol; 2000 Jul; 74(13):5747-53. PubMed ID: 10846052
[TBL] [Abstract][Full Text] [Related]
14. Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection.
Gao N; Wang W; Wang C; Gu T; Guo R; Yu B; Kong W; Qin C; Giorgi EE; Chen Z; Townsley S; Hu SL; Yu X; Gao F
AIDS; 2018 Mar; 32(5):555-563. PubMed ID: 29239895
[TBL] [Abstract][Full Text] [Related]
15. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
[TBL] [Abstract][Full Text] [Related]
16. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
[TBL] [Abstract][Full Text] [Related]
17. Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4
Obregon-Perko V; Bricker KM; Mensah G; Uddin F; Kumar MR; Fray EJ; Siliciano RF; Schoof N; Horner A; Mavigner M; Liang S; Vanderford T; Sass J; Chan C; Berendam SJ; Bar KJ; Shaw GM; Silvestri G; Fouda GG; Permar SR; Chahroudi A
J Virol; 2020 Dec; 95(2):. PubMed ID: 33087463
[TBL] [Abstract][Full Text] [Related]
18. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.
Julg B; Liu PT; Wagh K; Fischer WM; Abbink P; Mercado NB; Whitney JB; Nkolola JP; McMahan K; Tartaglia LJ; Borducchi EN; Khatiwada S; Kamath M; LeSuer JA; Seaman MS; Schmidt SD; Mascola JR; Burton DR; Korber BT; Barouch DH
Sci Transl Med; 2017 Sep; 9(408):. PubMed ID: 28931655
[TBL] [Abstract][Full Text] [Related]
19. Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection.
Desikan R; Raja R; Dixit NM
PLoS Comput Biol; 2020 Aug; 16(8):e1008064. PubMed ID: 32817614
[TBL] [Abstract][Full Text] [Related]
20. Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques.
Hsu DC; Sunyakumthorn P; Wegner M; Schuetz A; Silsorn D; Estes JD; Deleage C; Tomusange K; Lakhashe SK; Ruprecht RM; Lombardini E; Im-Erbsin R; Kuncharin Y; Phuang-Ngern Y; Inthawong D; Chuenarom W; Burke R; Robb ML; Ndhlovu LC; Ananworanich J; Valcour V; O'Connell RJ; Spudich S; Michael NL; Vasan S
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
